Blog
RSS FeedPosted by Michael Wonder on 14 Aug 2018
NICE would welcome further discussions about access to spinal muscular atrophy drug nusinersen
14 August 2018 - NICE hopes for further talks over nusinersen for treating a rare genetic disorder; spinal muscular atrophy. ...
Posted by Michael Wonder on 11 Aug 2018
CF patients furious as Vertex turns back on NICE
10 August 2018 - A group of cystic fibrosis patients could be denied access to a cutting-edge therapy after manufacturer ...
Posted by Michael Wonder on 10 Aug 2018
Biosimilars for insulin: a cost-saving alternative?
11 August 2018 - The expiry of patents on an insulin analogue has opened the market to the production of biosimilar ...
Posted by Michael Wonder on 09 Aug 2018
NICE changes its mind on Pfizer’s Besponsa
9 August 2018 - NICE has reversed its draft decision rejecting Pfizer’s Besponsa (inotuzumab ozogamicin) as a treatment for adults ...
Posted by Michael Wonder on 08 Aug 2018
Lenvatinib mesylate and sorafenib tosylate for the treatment of patients with differentiated thyroid cancer after the use of radioactive iodine
8 August 2018 - NICE has published evidence-based recommendations on the use of lenvatinib mesylate (Lenvima) and sorafenib tosylate (Nexavar) ...
Posted by Michael Wonder on 08 Aug 2018
Ixekizumab for treatment of adults with active psoriatic arthritis
8 August 2018 - NICE has published evidence-based recommendations on the use of ixekizumab (Taltz) on the NHS for the ...
Posted by Michael Wonder on 08 Aug 2018
NICE publishes draft guidance on new use for lenvatinib mesylate
8 August 2018 - The Department of Health and Social Care has asked NICE to produce guidance on using lenvatinib mesylate ...
Posted by Michael Wonder on 08 Aug 2018
NICE publishes final appraisal determination for Alecensa
8 August 2018 - The determination relates to the use of alectinib hydrochloride for the first-line treatment of patients with untreated ...
Posted by Michael Wonder on 08 Aug 2018
UK unveils plans for bigger medicines price squeeze
7 August 2018 - Company payments to government would rise steeply to 2021. ...
Posted by Michael Wonder on 07 Aug 2018
Government looks to include biosimilars in price controls
7 August 2018 - The government has launched consultation on proposed changes to the statutory scheme for pharmaceutical pricing that ...
Posted by Michael Wonder on 02 Aug 2018
NHS saved £324 million by switching to biosimilars and generics
2 August 2018 - The UK’s national healthcare provider saved £324 million by switching its patients to “better value” biosimilar ...
Posted by Michael Wonder on 02 Aug 2018
NICE publishes final appraisal determination for Sanofi's Dupixent
1 August 2018 - Dupilumab (Dupixent) is used to treat adults with moderate to severe atopic dermatitis. ...
Posted by Michael Wonder on 02 Aug 2018
Sanofi, Novartis latest to stockpile drugs in case of no-deal Brexit
1 August 2018 - Sanofi and Novartis action follows similar move by AstraZeneca. ...
Posted by Michael Wonder on 26 Jul 2018
NICE backing for Keytruda in classical Hodgkin's lymphoma
26 July 2018 - NICE has recommended that MSD’s Keytruda be funded on the NHS via the Cancer Drugs Fund ...
Posted by Michael Wonder on 24 Jul 2018
Prescribing biosimilars
24 July 2018 - Slow adoption is costly. ...